title: Recurrence incidence of small HCC in cirrhosis patients by ablation versus injection.
abstract: OBJECTIVE
  The incidence of local recurrence of hypervascular hepatocellular carcinoma (HCC) (15 mm or less) was compared retrospectively between a group treated with radiofrequency ablation (RFA) using cool-tip (Radionics, USA) 10-mm electrodes and a group treated with percutaneous ethanol injection (PEI).
  
  
  METHODS
  There were 23 patients who were treated for a total of 25 tumors during a 3-year period at our hospital. Ten of the tumors (11.1 +/- 2.7mm) were treated with RFA using cool-tip 10-mm electrodes and 15 tumors (10.6 +/- 2.7 mm) were treated with PEI. After treatment, progression was evaluated in enhanced CT scans every 3-6 months to confirm presence or absence of local recurrence.
  
  
  RESULTS
  The number of recurrences, mean observation period, and mean recurrence period in the RFA group were 2 (20%), 6.6 months, and 6 months. The number of recurrences, mean observation period, and mean recurrence period in the PEI group were 2 (13.3%), 19.1 months, and 18 months. The period between treatment and recurrence tended to be longer in the PEI group than in the RFA group to be significant p < 0.05.
  
  
  CONCLUSIONS
  The results suggest that PEI treatment is more effective in local treatment of hypervascular HCC with tumor diameters of 15 mm or less.
authors.affiliation: Division Of Gastroenterology and Hepatology, Toho University Omori Medical Center, 6-11-1, Omorinishi, Ota-ku, Tokyo, Japan 143-8541. noriwakui@yahoo.co.jp
authors.forename: Noritaka
authors.initials: N
authors.lastname: Wakui
authors.forename: Kazunari
authors.initials: K
authors.lastname: Iida
authors.forename: Takashi
authors.initials: T
authors.lastname: Ikehara
authors.forename: Ryuji
authors.initials: R
authors.lastname: Takayama
authors.forename: Kazue
authors.initials: K
authors.lastname: Shiozawa
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Hidenari
authors.initials: H
authors.lastname: Nagai
authors.forename: Manabu
authors.initials: M
authors.lastname: Watanabe
authors.forename: Koji
authors.initials: K
authors.lastname: Ishii
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Igarashi
authors.forename: Yasukiyo
authors.initials: Y
authors.lastname: Sumino
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015994:Incidence; D015552:Injections, Intralesional; D007564:Japan / Q000453:epidemiology; D008103:Liver Cirrhosis / Q000150:complications / Q000453:epidemiology; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000431:Ethanol